| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0306-4522(93)90364-L |
| P698 | PubMed publication ID | 8305078 |
| P2093 | author name string | Conti M | |
| Corbin JG | |||
| Goy MF | |||
| Repaske DR | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 14 | |
| P304 | page(s) | 673-686 | |
| P577 | publication date | 1993-10-01 | |
| P1433 | published in | Neuroscience | Q15708571 |
| P1476 | title | A cyclic GMP-stimulated cyclic nucleotide phosphodiesterase gene is highly expressed in the limbic system of the rat brain | |
| P478 | volume | 56 |
| Q42272474 | A novel role for cyclic guanosine 3',5'monophosphate signaling in synaptic plasticity: a selective suppressor of protein kinase A-dependent forms of long-term potentiation. |
| Q28506723 | A phosphodiesterase 2A isoform localized to mitochondria regulates respiration |
| Q48656687 | Autoradiographic characterization of [3H]cGMP binding sites in the rat brain |
| Q39072124 | Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease? |
| Q28575617 | Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase |
| Q28392899 | Cross-regulation of Phosphodiesterase 1 and Phosphodiesterase 2 Activities Controls Dopamine-mediated Striatal α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Trafficking |
| Q22010143 | Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells |
| Q48403303 | Distribution of nitric oxide synthase and nitric oxide-receptive, cyclic GMP-producing structures in the rat brain |
| Q28511192 | Dual acylation of PDE2A splice variant 3: targeting to synaptic membranes |
| Q48384641 | Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex |
| Q48718544 | Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. |
| Q41732106 | GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease revisited |
| Q41039991 | GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease; pharmacologic profile of the benzodiazepine antagonist, flumazenil |
| Q28581263 | Immunohistochemical localization of PDE10A in the rat brain |
| Q24337499 | Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species |
| Q28117232 | Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3′,5′-cyclic nucleotide phosphodiesterase |
| Q73199657 | Localization of the cGMP-dependent protein kinases in relation to nitric oxide synthase in the brain |
| Q48155193 | Molecular comparison of rat cyclic nucleotide phosphodiesterase 8 family: unique expression of PDE8B in rat brain |
| Q28268016 | Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A |
| Q48290989 | Monitoring neuronal NO release in vivo in cerebellum, thalamus and hippocampus. |
| Q31962204 | Nerve growth factor inhibits PC12 cell PDE 2 phosphodiesterase activity and increases PDE 2 binding to phosphoproteins. |
| Q48290923 | Nitric oxide as a retrograde messenger during long-term potentiation in hippocampus. |
| Q33881680 | Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. |
| Q47732763 | Phosphodiesterase Diversity and Signal Processing Within cAMP Signaling Networks. |
| Q42513937 | Phosphodiesterase type 2 and the homeostasis of cyclic GMP in living thalamic neurons |
| Q36514530 | Phosphodiesterases and adrenal Cushing in mice and humans |
| Q28279704 | Phosphodiesterases as therapeutic targets for Alzheimer's disease |
| Q28255355 | Phosphodiesterases in the CNS: targets for drug development |
| Q49098718 | Presynaptic role of cGMP-dependent protein kinase during long-lasting potentiation. |
| Q48708648 | Regulation of cyclic GMP levels in the rat frontal cortex in vivo: effects of exogenous carbon monoxide and phosphodiesterase inhibition |
| Q47732711 | Role of Phosphodiesterases in Huntington's Disease |
| Q37252748 | Role of phosphodiesterase 5 in synaptic plasticity and memory |
| Q37245947 | Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. |
| Q44847927 | Species differences in the localization of cGMP-producing and NO-responsive elements in the mouse and rat hippocampus using cGMP immunocytochemistry. |
| Q37317832 | The NO/cGMP pathway inhibits transient cAMP signals through the activation of PDE2 in striatal neurons. |
| Q35538783 | The distribution of phosphodiesterase 2A in the rat brain. |
| Q43517525 | The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. |
| Q42512114 | The nitric oxide system modulates the in vivo release of acetylcholine in the nucleus accumbens induced by stimulation of the hippocampal fornix/fimbria-projection |
| Q48597401 | The role of cyclic AMP as a precursor of extracellular adenosine in the rat hippocampus |
| Q24538689 | The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding |
| Q54225221 | [Physiopathology of cAMP/PKA signaling in neurons]. |
| Q47378008 | mRNA expression patterns of the cGMP‐hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain |
Search more.